CNTA vs. ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, NUVL, LNTH, TLX, and AXSM
Should you be buying Centessa Pharmaceuticals stock or one of its competitors? The main competitors of Centessa Pharmaceuticals include Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.
Centessa Pharmaceuticals vs. Its Competitors
Centessa Pharmaceuticals (NASDAQ:CNTA) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.
Centessa Pharmaceuticals presently has a consensus price target of $27.89, suggesting a potential upside of 75.35%. Roivant Sciences has a consensus price target of $16.50, suggesting a potential upside of 41.94%. Given Centessa Pharmaceuticals' higher probable upside, equities research analysts clearly believe Centessa Pharmaceuticals is more favorable than Roivant Sciences.
82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 7.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 7.9% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Centessa Pharmaceuticals has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.
In the previous week, Roivant Sciences had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 5 mentions for Roivant Sciences and 4 mentions for Centessa Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.16 beat Centessa Pharmaceuticals' score of 0.80 indicating that Roivant Sciences is being referred to more favorably in the news media.
Centessa Pharmaceuticals has a net margin of 0.00% compared to Roivant Sciences' net margin of -225.71%. Roivant Sciences' return on equity of -14.76% beat Centessa Pharmaceuticals' return on equity.
Roivant Sciences has higher revenue and earnings than Centessa Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Roivant Sciences beats Centessa Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Centessa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Centessa Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CNTA) was last updated on 7/17/2025 by MarketBeat.com Staff
Free CNTA Stock Alerts